Clinical Trial Detail

NCT ID NCT02289898
Title Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors OncoMed Pharmaceuticals, Inc.
Indications

pancreatic ductal adenocarcinoma

Therapies

Demcizumab + Gemcitabine + Nab-paclitaxel

Age Groups: adult

No variant requirements are available.